| Previous close | 5.40 |
| Open | 5.42 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 430.00 |
| Expiry date | 2025-12-19 |
| Day's range | 5.40 - 5.42 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksWill These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
ZacksShould You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
ZacksDown -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
© 2024 Yahoo. All rights reserved.